Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
5-Amino-1MQ vs AOD-9604
An educational, source-based comparison of 5-Amino-1MQ and AOD-9604 — how each peptide works, what it's researched for, and what to know before going deeper.
Not a peptide but commonly grouped in peptide research. A selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Inhibition increases SAM and NAD+ availability, increasing adipocyte energy expenditure in animal models.
- Diet-induced obesity (rodent)
- White adipose tissue energy expenditure
- Age-related muscle function
- • Investigational; no human clinical trials yet.
- • Not FDA-approved.
A modified 16-amino-acid fragment (177–191) of human growth hormone, engineered to retain the lipolytic activity of GH without its growth or insulin-resistance effects. Research suggests it stimulates lipolysis and inhibits lipogenesis.
- Obesity (clinical trials did not meet endpoints)
- Osteoarthritis / cartilage repair (current research direction)
- Localized adipose research
- • Not FDA-approved as a therapeutic.
- • Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition reduces adiposity in obese mice | Nature Medicine | 2015 | Demonstrated weight loss and improved metabolic profile via NNMT inhibition. |
| AOD-9604 | AOD9604 in obesity: phase 2b results | Obesity | 2010 | Did not achieve significant weight loss vs. placebo in primary endpoint. |
Side-effect & safety grid
- Investigational; no human clinical trials yet.
- Not FDA-approved.
- Not FDA-approved as a therapeutic.
- Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
5-Amino-1MQ vs AOD-9604 — Key differences
- Class: 5-Amino-1MQ is classified as Metabolic · Small Molecule, while AOD-9604 is Metabolic · Lipolysis.
- Primary research focus: 5-Amino-1MQ — diet-induced obesity (rodent); AOD-9604 — obesity (clinical trials did not meet endpoints).
- Tag: Metabolic vs Fat loss.